Liquidia Technologies, a company developing an inhaled form of treprostinil for pulmonary arterial hypertension (PAH), has established an…
Articles by Inês Martins, PhD
Gene expression patterns in the lungs can help distinguish pulmonary arterial hypertension (PAH) from pulmonary veno-occlusive disease (PVOD)…
Aerami Therapeutics has entered an agreement with Vectura Group to develop and commercialize an inhaled form of…
A composite assessment of voice features may be able to monitor changes in the pulmonary arteries of people with…
Chronic inhalation of nicotine, the addictive component of all tobacco products, is enough to trigger changes in pulmonary arteries…
Tricumed‘s LENUS Pro pump, an implantable device approved in Europe for the long-term intravenous administration of Remodulin…
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to…
Despite previous evidence to the contrary, a single-center study suggests that sex hormones do not influence the development or progression…
Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are successfully treated with pulmonary endarterectomy (PEA) may be at increased risk…
People infected with HIV are known to have a greater incidence of pulmonary hypertension and to be an almost 2,500-fold higher risk…
The vascular constrictor coupling factor 6 (CF6) is involved in the development of pulmonary arterial hypertension by creating an imbalance in…
Reata Pharmaceuticals recently provided an update on its clinical candidates and their developmental, including its Phase 2 proof-of-concept studies into bardoxolone…